Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
Open Access
- 7 March 2008
- journal article
- research article
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 9 (1) , 32
Abstract
The efficacy, safety and tolerability of lumiracoxib, a novel selective cyclooxygenase-2 (COX-2) inhibitor, has been demonstrated in previous studies of patients with osteoarthritis (OA). As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA, the present study compared the effects of lumiracoxib at doses of 100 mg once daily (o.d.) and 100 mg twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year.Keywords
This publication has 31 references indexed in Scilit:
- Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of goutRheumatology, 2007
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- P309 BLOOD PRESSURE PROFILE OF LUMIRACOXIB IS SIMILAR TO PLACEBO IN ARTHRITIS PATIENTSOsteoarthritis and Cartilage, 2006
- Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritisClinical Therapeutics, 2005
- Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxibCurrent Medical Research and Opinion, 2005
- Efficacy of Lumiracoxib in Osteoarthritis: A Review of Nine StudiesJournal of International Medical Research, 2005
- Efficacy and tolerability of lumiracoxib in the treatmentof osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placeboClinical Therapeutics, 2005
- Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trialsPain, 2004
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- COX-2 inhibitorsThe Lancet, 1999